Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVOK Evoke Pharma	$5.12 -0.4%	$4.01	$1.94 ▼ $12.32	$7.64M	-0.04	108,363 shs	29,307 shs
KZR Kezar Life Sciences	$3.97 -0.3%	$4.35	$3.62 ▼ $9.18	$29.07M	0.65	44,551 shs	42,565 shs
MIRA MIRA Pharmaceuticals	$1.50 +2.0%	$1.42	$0.73 ▼ $2.70	$28.60M	1.77	561,375 shs	272,804 shs
MURA Mural Oncology	$1.76 -0.6%	$2.32	$0.95 ▼ $4.74	$30.49M	3	277,977 shs	82,754 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVOK Evoke Pharma	0.00%	-5.88%	+11.06%	+59.01%	-11.42%
KZR Kezar Life Sciences	0.00%	-1.00%	-10.99%	-2.46%	-34.86%
MIRA MIRA Pharmaceuticals	0.00%	+8.70%	-25.74%	+3.45%	-22.28%
MURA Mural Oncology	0.00%	+10.69%	-29.32%	-33.58%	-44.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVOK Evoke Pharma	0.5414 of 5 stars	0.0	5.0	0.0	1.8	0.0	0.0
KZR Kezar Life Sciences	3.8278 of 5 stars	3.2	0.0	4.6	1.9	3.3	0.6
MIRA MIRA Pharmaceuticals	3.2451 of 5 stars	3.8	5.0	0.0	3.3	0.0	0.6
MURA Mural Oncology	3.1635 of 5 stars	3.3	3.0	0.0	2.7	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVOK Evoke Pharma	0.00	N/A	N/A	N/A
KZR Kezar Life Sciences	2.33	Hold	$9.00	126.70% Upside
MIRA MIRA Pharmaceuticals	3.50	Strong Buy	$17.00	1,033.33% Upside
MURA Mural Oncology	2.50	Moderate Buy	$12.00	581.82% Upside

Current Analyst Ratings Breakdown

Latest EVOK, MURA, KZR, and MIRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVOK Evoke Pharma	$10.25M	0.74	N/A	N/A	$4.74 per share	1.08
KZR Kezar Life Sciences	$7M	4.15	N/A	N/A	$12.53 per share	0.32
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	$3.39 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVOK Evoke Pharma	-$5.35M	-$2.56	N/A	∞	N/A	-42.07%	-93.51%	-33.60%	11/5/2025 (Estimated)
KZR Kezar Life Sciences	-$83.74M	-$9.69	N/A	N/A	N/A	N/A	-63.51%	-52.13%	N/A
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.49	N/A	N/A	N/A	N/A	-329.63%	-271.22%	N/A
MURA Mural Oncology	-$128.51M	-$8.59	N/A	N/A	N/A	N/A	-107.76%	-87.57%	N/A

Latest EVOK, MURA, KZR, and MIRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EVOK Evoke Pharma	-$0.30	-$0.62	-$0.32	-$0.62	$3.80 million	$3.75 million
8/14/2025	Q2 2025	MIRA MIRA Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	N/A	N/A
8/13/2025	Q2 2025	KZR Kezar Life Sciences	-$2.15	-$1.87	+$0.28	-$1.87	N/A	N/A
8/4/2025	Q2 2025	MURA Mural Oncology	-$1.13	-$1.77	-$0.64	-$2.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVOK Evoke Pharma	N/A	1.55	1.50
KZR Kezar Life Sciences	0.03	7.29	7.09
MIRA MIRA Pharmaceuticals	N/A	12.86	12.86
MURA Mural Oncology	N/A	2.87	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVOK Evoke Pharma	N/A
KZR Kezar Life Sciences	67.90%
MIRA MIRA Pharmaceuticals	35.16%
MURA Mural Oncology	80.21%

Insider Ownership

Company	Insider Ownership
EVOK Evoke Pharma	2.29%
KZR Kezar Life Sciences	10.40%
MIRA MIRA Pharmaceuticals	6.65%
MURA Mural Oncology	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVOK Evoke Pharma	4	1.49 million	1.46 million	Not Optionable
KZR Kezar Life Sciences	60	7.32 million	6.56 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	19.07 million	17.80 million	Not Optionable
MURA Mural Oncology	119	17.32 million	16.94 million	Optionable

EVOK, MURA, KZR, and MIRA Headlines

Recent News About These Companies

Why some in Columbia cared so much about saving Hunter-Gatherer’s bricks & mural

August 14 at 10:03 AM | thestate.comT

Mural Oncology (MURA) to Release Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Mural Oncology (NASDAQ:MURA) Cut to Strong Sell at Wall Street Zen

August 10, 2025 | americanbankingnews.com

Colourful mural celebrates 10 years of cancer care at WWL

August 4, 2025 | msn.com

Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

August 4, 2025 | globenewswire.com

Artists help pupils and centre users create murals

August 3, 2025 | msn.com

Baltimore honors Henrietta Lacks with community-painted mural

August 2, 2025 | msn.com

Baltimore community comes together to complete Henrietta Lacks mural

August 2, 2025 | wmar2news.comW

Community news: Mural walk, health fair, digital skill lessons

July 28, 2025 | chicagotribune.com

New mural inspires student growth on the Eastern Shore

July 28, 2025 | msn.com

Downtown Raleigh’s history unfolds in a sprawling new mural. Who is on it?

July 28, 2025 | msn.com

Can Mural Oncology (NASDAQ:MURA) Afford To Invest In Growth?

July 23, 2025 | finance.yahoo.com

Minneapolis muralist honors Tuskegee airmen

July 19, 2025 | msn.com

Mural Oncology, Inc.: Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - FinanzNachrichten.de

July 8, 2025 | finanznachrichten.de

Demolition threatens breast cancer mural in 12 Points community

July 5, 2025 | wthitv.comW

Building that features the PINK of Terre Haute wings mural to be demolished

July 4, 2025 | msn.com

'Vibrancy': New murals proposed for Downtown Peoria parking decks

July 3, 2025 | msn.com

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

June 16, 2025 | markets.businessinsider.com

BlackRock discloses 1.64% stake in Mural Oncology

June 13, 2025 | investing.com

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc

June 13, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVOK, MURA, KZR, and MIRA Company Descriptions

Evoke Pharma NASDAQ:EVOK

$5.12 -0.02 (-0.39%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.94 -0.18 (-3.42%)

As of 08/15/2025 07:56 PM Eastern

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Kezar Life Sciences NASDAQ:KZR

$3.97 -0.01 (-0.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.09 +0.12 (+2.92%)

As of 08/15/2025 07:56 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.50 +0.03 (+2.04%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.02 (-1.33%)

As of 08/15/2025 07:59 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Mural Oncology NASDAQ:MURA

$1.76 -0.01 (-0.56%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.79 +0.03 (+1.70%)

As of 08/15/2025 05:03 PM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time